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Summary 
Though CD44 functions as a cell surface receptor for hyaluronan (HA) in some cell lines,  most 
normal hematopoietic cells expressing CD44 do not bind HA. Certain CD44-specific monoclonal 
antibodies (mAbs) can rapidly induce CD44-mediated HA binding in normal routine T  ceils. 
This observation suggests that  in vivo mechanisms  may exist for activating  the HA receptor 
function of CD44 on normal T  ceils.  Here, it is shown that up to one third of splenic T  cells 
are capable of CD44-mediated binding of fluorescein-conjugated HA (F1-HA) during an in vivo 
allogeneic response. HA binding activity peaks at 7-8 d postinjection and declines rapidly. These 
rapid kinetics could be the result of transient activation of CD44 function and/or differentiation 
or expansion of short-lived population(s) that have constitutive HA-binding function. Both CD4 
and CD8 T cells are included in the HA binding population which is strongly CD44 positive. 
After separation  of HA-binding  cells  from nonbinding  cells by cell sorting,  it is shown that 
almost all cytotoxic effector cells are found in the HA-binding population.  However, there is 
no evidence that  CD44-mediated  HA recognition is directly involved in the killing of target 
cells, since cytotoxicity could not be inhibited by CD44-specific mAbs that inhibit HA binding 
or by soluble HA. PCR amplification of cDNA reverse transcribed from RNA of sorted HA- 
binding cells indicated no evidence for CD44 isoforms other than the standard (hematopoietic) 
form. Though CD44 expression is known to be elevated upon T  cell activation, and, as shown 
here, HA-binding function is induced in a portion of CD44-expressing T cells including cytotoxic 
effector cells,  the role of CD44  and HA-recognition  in immune  responses is not  known. 
T 
he cell surface glycoprotein CD44 is an adhesion receptor 
for extracellular matrix molecules that has been impli- 
cated in lymphocyte recirculation, cell migration, T cell sig- 
naling,  cell-cell interactions,  and metastasis (1-3).  Though 
a number of ligands have been proposed for CD44, its inter- 
action with the glycosaminoglycan hyaluronan (HA) is the 
most thoroughly documented (1, 3-5). Nevertheless, many 
normal cells that express CD44 do not bind HA (1, 6,  7). 
Thus, whether HA-recognition is involved in the biological 
functions proposed for CD44 is not yet established. 
It has been suggested that CD44, like a number of other 
adhesion receptors of hematopoietic cells, may be inactive in 
resting cells and may require specific activation events to in- 
duce its  ligand-recognition  function  (6,  7).  Though  HA 
binding cells are not detected in resting populations of normal 
murine hematopoietic cells, Murakami et al. (8, 9) have shown 
that  a population of B cells capable of binding HA can be 
induced by graft vs. host reaction in vivo or by culture for 
several days in IL-5. Also, a CD44-specific mAb (IR_AWB14) 
has been described that can rapidly activate HA binding by 
CD44 on some T  cells (6, 7), suggesting that physiological 
mechanisms may exist for activation  of CD44 function in 
T  cells. In the present study, we examined whether CD44- 
mediated HA binding was induced in T cells after immuno- 
logical stimulation in vivo. A strong allogeneic response was 
used as a model in order to induce sufficient numbers of cells 
to be detected by flow cytometry. 
Materials and Methods 
Animals and Immunization.  4-6-wk-old C57BL/6 (H2  b) and 
DBA/2 (H2  a) mice were purchased from Harlan-Sprague Dawley 
Inc. (Indianapolis, IN). P815 (DBA/2 origin,  H2  d) mastocytoma 
cells were maintained in suspension culture  in DME with 10% 
calf serum. C57BL/6 mice were injected i.v. or i.p. with 107 P815 
cells or with 2  ￿  107 DBA/2 spleen cells. Spleen, bone marrow, 
peripheral lymph nodes  (brachial and inguinal),  and mesenteric 
lymph nodes were harvested at various times after immunization 
and single cell suspensions prepared. 
Flow Cytometry and Cell Sorting.  Cells were labeled with fluo- 
rescein-conjugated hyaluronan (FI-HA) as previously described (6, 
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HA (250/~g/ml) or with the CD44-specific mAb KM201 (4) which 
inhibits HA binding to CD44 (see Fig. 2). For two-color studies, 
biotin-conjugated mAbs specific for other lymphocyte cell surface 
molecules were detected with phycoerythrin-streptavidin (Biomeda 
Corp., Foster City, CA) as described previously (6).  These bio- 
tinylated mAb included 57.597 for TCR-oe/3, 53.6.72 for CD8, 
GK1.5 for CD4, Mel-14 for L-selectin, RA3.2C2 and RA3.6B2 
for B220 (B ceil-specific  CD45),  RB6.8C5 for the myeloid lin- 
eage,  and M1/70 for Mac-1. 
Cells  stained  for one- (fluorescein)  or  two-  (fluorescein  and 
phycoerythrin) color fluorescence were run on a FACScan §174  flow 
cytometer (Becton Dickinson & Co., Mountain View, CA). Cell 
sorting was  carried out on a FACStar §174  (Becton Dickinson & 
Co.) using total spleen cells stained  with F1-HA.  Sort windows 
for F1-HA positive and negative cells were chosen on the basis of 
control staining with F1-HA in the presence of 250 mg/ml of unla- 
beled HA. A window composed at 5-10% of the total cells, be- 
tween the F1-HA positive and negative populations, was discarded. 
Cell-mediated Cytotoxic Assays.  Target P815 cells were labeled 
with SaCr and distributed into 96-well V-bottom microtiter plates 
(Dynatec Laboratories, Inc., Chantilly, VA) at 2  x  104 cells/well. 
Stained and sorted spleen cell populations were added to wells at 
the ratios indicated in Fig. 4. Plates were incubated for 3-4 h, the 
cells centrifuged into a pellet, and 100/~1 of supernatant removed 
and counted. In other experiments, total (unsorted) spleen cells 
(at ratios of 1:10, 1:50, 1:200) were added to SlCr-labeled P815 cells 
in the presence of mAb (1:6 dilution of hybridoma supernatant) 
or unlabeled HA (335 mg/ml). Each ratio for each condition was 
assayed in triplicate.  Percent cytotoxicity was calculated as follows: 
Percent cytotoxicity =  (experimental SXCr release  -  spontaneous 
SlCr release)/(maximal SlCr release  -  spontaneous SlCr release) 
x  100. Spontaneous release  was  determined by culturing s~Cr- 
labeled P815 cells in the absence of C57BL/6 spleen cells. Maximal 
release was determined by adding 1% NP-40 in 0.1 N  NaOH to 
wells containing S~Cr-labeled target cells. 
Reverse Transc@tion and PCR Amplification (RT-PCR) of RNA 
from Sorted Spleen Cells.  Total cellular RNA  from sorted HA- 
binding (1.2  x  106) and nonbinding (1.6  x  106) cells was isolated 
using an RNA isolation kit (Stratagene, La Jolla, CA). 5  x  106 
AKR1 cells transfected with murine M1 and M2 isoforms of CD44 
(containing variant exons v9-10 and v8-10, respectively), as described 
in (10), were treated identically.  30% of total cellular RNA from 
the sorted cells and 10% from control cells were used as templates 
for the synthesis of eDNA. First strand syntheses were carried out 
for 2 h at 37~  using 200 U reverse transcriptase (Superscript;  Life 
Technologies,  Grand Island,  NY) with the following primer: 5' 
GTTCACCAAATGCACCATTTCCTG 3'. The cDNA products 
(two-fifths of the total for sorted cells, three-tenths for control cells) 
were then used as template for PCR using 2.5 U Taq polymerase 
(Stratagene) with the aforementioned 3' primer located 288 bp 
downstream of the insertion site (insertion site corresponds to po- 
sition 704 in reference 11) and the 5' primer located 74 bp upstream 
of the insertion site with the sequence 5' TACCTTCCTACTGAA- 
CAGCCCTACTGGGAAGAT Y. After purification the PCR prod- 
ucts were run on an agarose gel (one-tenth of PCR product in 
all cases), transferred to a Nylon membrane (Hybond-N; Amer- 
sham Corp.; Arlington Heights, IL), and hybridized with a radio- 
labeled CD44-specific probe (nucleotides 700-1183).  The blot was 
exposed to x-ray film for 2 d. The film was scanned on a Scan Jet 
Ilcx/T (Hewlett-Packard Co., Palo Alto, CA). Canvas 3.5.1  soft- 
ware was used for contrast adjustment and labeling the image, and 
the printer was  a Phaser II SDX (Tektronix, Wilsonville, OR). 
Results  and  Discussion 
Induction of HA-binding Cells in Spleen.  C57BL/6 (H2  b) 
mice  were  immunized  with  P815  (DBA/2  origin,  H2  d) 
mastocytoma cells to induce an allogeneic response. Hema- 
topoietic and lymphoid tissues were assayed by flow cytom- 
etry for the presence of cells capable of binding F1-HA. Unim- 
munized  mice  had  no  detectable  HA-binding  cells.  Mice 
immunized intravenously had detectable levels of HA-binding 
cells in the spleen between days 5 and 10 post injection (Fig. 
1).  In these same mice, no HA-binding cells were detected 
in lymph nodes or bone marrow. Examples of HA-binding 
in total spleen cell populations from mice 6, 7, and 8 d after 
intravenous injection of P815 cells are shown in Fig. 2 (first 
row). Specificity and CD44 dependence of the HA binding 
activity were verified by inhibition of F1-HA binding with 
excess unlabeled  HA  (Fig.  2, dotted insets) or with  CD44- 
specific mAb KM201  (Fig.  2, second row), which has been 
shown to block the HA-binding function of CD44 (4). HA 
binding was very heterogeneous,  and dull cells often over- 
lapped the background staining measured in the presence of 
unlabeled HA  (see Fig.  2).  Also,  as can be seen from Fig. 
1, the proportion of HA binding cells in immunized spleens 
varied greatly among individual mice. HA-binding cells de- 
tectable in the spleen declined after 9  d.  The transient  ap- 
pearance of HA binding activity could be due to transient 
activation of CD44/HA-binding function and/or to differen- 
tiation or expansion of short-lived population(s) of constitu- 
tive HA-binding  cells. 
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Percentage of HA  binding  cells in  the  spleens of C57 
BL/6(H2 b) mice undergoing an allogeneic immune response to P815 
(H2  a) cells. Total nucleated cells from the spleens of individual mice in- 
jected with 107 P815 cells i.v. were prepared at the indicated times post 
injection, stained with FI-HA, and analyzed by flow cytometry. The per- 
cent of total spleen cells binding HA was determined by comparison  with 
control cells stained with FI-HA in the presence of excess unlabeled HA 
as follows: a cursor was set so that (2% of control ceils were positive 
(with a staining intensity beyond cursor); this background percent was 
then subtracted from the percentage of positive cells observed in the ab- 
sence of unlabeled HA using the same cursor setting. In unimmunized 
mice, there was a (1% difference  between cells stained with FI-HA in 
the presence or absence of unlabeled HA. 
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Figure 2.  Representative  F1- 
HA staining of total spleen cells 
from P815 immunized C57BL/6 
mice. At the indicated days post 
injection,  total spleen cells were 
prepared and stained with F1-HA 
alone (top), or with FI-HA in the 
presence  of  the  CD44-specific 
mAb KM201 (bottom), which in- 
hibits  HA  binding  to  CD44 
(references 4, 7). The dotted line 
in both rows indicates the staining 
with F1-HA in the presence of 
excess unlabeled HA (250/~g/ml). 
In other experiments not shown, mice immunized by in- 
traperitoneal injection of P815 (107 cells) also had detectable 
levels of HA-binding cells in the spleen, but the percentage 
of HA-binding cells was generally lower than with i.v. injec- 
tion and peaked later, at about 10 d after injection.  HA-binding 
cells were not detected in the peritoneal cavity at 8,  10, or 
12 d, or in the lymph nodes of these intraperitoneally in- 
jected mice.  Mice immunized intravenously with DBA/2 
spleen cells (2  x  107) instead of P815 mastocytoma cells had 
lower, but detectable, numbers of HA binding cells in the 
spleen at 7 d  after immunization. 
Phenotype of HA-binding Cells in the Spleen.  Two-color flow 
cytometry was used to assess the phenotype of the HA-binding 
cells in spleen. Because the F1-HA staining was heterogeneous, 
the number of positive cells was often low, and the positive 
cells were not dearly separated from the background, it was 
difficult to determine more than a general picture of the pheno- 
type of HA-binding cells based on data from numerous ex- 
periments. Most HA-binding cells were T cells (67-90% in 
12 experiments) by virtue of their staining with mAbs against 
TCR-ot/fl (Fig. 3 C). In the maximum responses observed, 
HA-binding cells represented up to one-third of the splenic 
T  cells. The HA + cells were among the brightest CD44 + 
cells. They included CD8 + and CD4 + cells in proportion 
to the distribution of these cells in the total spleen T  cell 
population (Fig. 3, E and F). The HA-binding cells that were 
not T  cells included B cells and small numbers of myeloid 
cells (not shown). 
Attempts  to  enrich  for  HA +  cells  other  than  by cell 
sorting were unsuccessful. Panning on HA immobilized on 
plastic followed by recovery of cells with hyaluronidase gave 
low recoveries and did  not  significantly enrich for HA + 
cells, indicating that many F1-HA binding cells did not ad- 
here, unlike the HA-binding B cells described by Murakami 
et al. (6, 7). Procedures to enrich for T cells such as removal 
of B cells by panning on anti-Ig-coated plates  or by nylon 
wool columns also did not enrich for HA-binding cells. In- 
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Figure 3.  Two-color flow cytometry analysis of HA-binding cells of 
1)815 immunized  C57BL/6 mice at 7 d post injection. Total nucleated spleen 
cells were stained with F1-HA and biotin-conjugated mAb specific  for lym- 
phocyte surface-molecules as follows: mAb 57-597 specific for TCR-c~/3 
(C); mAb GK1.5 specific for CD4 (E); mAb 53-6-72 specific for CD8 
(F). Biotin-conjugated mAb were detected with phycoerythrin-streptavidin. 
Controls included cells stained with FI-HA in the presence of unlabeled 
HA (250/~g/ml) and with phycoerythrin-streptavidin (.4 and D); and cells 
stained with F1-HA and phycoerythrin-streptavidin (/3). A-C are from one 
experiment and D-F are from another experiment. 
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lation by passage over nylon wool. HA-binding cells enriched 
by cell sorting, and restained with biotinylated mAb against 
other cell surface markers, were all strongly CD44 positive 
and otherwise gave the same general staining pattern described 
above for two-color analysis of total spleen (data not shown). 
Cytotoxic Function of HA-binding Cells.  HA + and HA- 
populations were isolated from F1-HA stained spleen by cell 
sorting as described in Materials and Methods. The positive 
and negative populations and control stained and sorted cells 
(all live cells within the forward scatter range used for the 
positive and negative populations) were assayed for cytotoxic 
activity using 51Cr-labeled P815 targets. As can be seen in 
Fig. 4, almost all cytotoxic activity recovered  after sorting 
was found in the HA-binding fraction of the spleen,  which 
was enriched in cytotoxic activity compared with stained only 
or control-sorted cells. Thus, the HA-binding cells induced 
by immunization included the cytotoxic cell population. Since 
not all of the HA-binding cells are cytotoxic effectors, other 
functional T cells may be represented in the HA-binding popu- 
lation. 
The question as to whether CD44 binding to HA is directly 
involved in the cytotoxic function of effector cells was ad- 
dressed by the inclusion of soluble HA and mAb specific for 
CD44 in the cytotoxic assay. None of the mAbs tested, in- 
cluding several that block CD44-mediated HA binding, in- 
hibited  the cytotoxicity of effector cells.  Excess  HA  (335 
/~g/ml) was slightly inhibitory at low effector/target cell ratios, 
but this might be due to physical interference with cell-cell 
contacts because  of the increased  viscosity of the medium. 
Variant CD44 Isoforms.  Alternative splicing in the extracel- 
lular domain of CD44  can give rise to isoforms of CD44 
with higher molecular weights than the hematopoietic or 
"standard" isoform expressed  on all hematopoietic cells (1, 
12). Though these variant isoforms are only rarely expressed 
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Figure 4.  Cytotoxicity  of spleen cells from C57BL/6 mice 7 d after 
immunization  separated  by cell sorting  into HA-binding  (HA +) and non- 
binding (HA-) populations. F1-HA stained total spleen cells were sepa- 
rated by cell sorting  on a FACStar  +  |  as described  in Materials  and Methods. 
Sorted and control  populations  were assayed  for cytotoxicity  at the indi- 
cated ratios of spleen cells (effector)  to slCr-labeled  P815 cells (target) as 
described in Materials  and Methods.  A and B are two independent  experi- 
ments. In A, the control  population  was stained  with F1-HA  as for sorting, 
but was not sorted. In B, the control  population  was stained  with F1-HA 
and sorted using the same scatter and dead cell gates used for the ex- 
perimental  populations,  but with no windows  set on fluorescein  fluorescence. 
on normal resting cell types, they are often found on tumor 
cells and, in certain situations, may contribute to metastasis 
(13). Using a mAb specific for alternate exons of higher Mr 
variant isoforms of rat CD44, Arch et al. (14) detected tran- 
sient expression of variant CD44 isoforms on cells from lym- 
phatic tissues of rats undergoing allogeneic responses.  Since 
no mAbs are yet available to detect variant isoforms of mu- 
rine CD44, we used reverse transcription of RNA from sorted 
HA-binding and nonbinding cells, followed by PCR amplifica- 
tion, to determine the CD44 isoform(s) expressed in these 
populations.  As shown by Southern blot of the RT-PCR 
products in Fig.  5,  only RNA of the standard isoform of 
CD44 was detected in both HA + (Fig. 5, lane A) and HA- 
(Fig. 5, lane B) populations. To verify that the procedure would 
detect larger isoforms of CD44, AKR1 lymphoma cells trans- 
fected with CD44 isoforms containing variant exons (described 
in  reference  10)  were  processed  in  parallel  (Fig.  5,  lanes 
C and D). 
CD44 in Immune Responses.  It has been known for some 
time that CD44 is upregulated upon T  cell activation and 
remains elevated in memory T cells (15-17), but the possible 
role of CD44 in T  cell function is not known. A number 
of reports  have presented evidence  that CD44  can deliver 
costimulatory signals to T cells upon ligation (see references 
1 and 2). In these in vitro studies, stimulation through CD44 
was mediated by CD44-specific  mAbs, as the natural ligand 
for CD44 was not known. A number of more recent studies 
have implicated CD44 in immunological responses in vivo: 
(a) Mobley and Dailey (18) found a unique population of 
CD44  hi, Mel-14 l~ CD8 + T cells at the site of graft rejection 
and as a very rare population in draining lymph nodes; (b) 
Camp et al. (19) showed that mAb-induced stripping of  CD44 
from the surface of lymphocytes retarded a delayed hypersen- 
sitivity response  (measured by ear swelling) for 24 h;  and 
(c) Rodrigues et al.  (20)  found that the ability of malaria- 
reactive cloned cytotoxic cell lines to protect malaria-infected 
mice correlated with high CD44 expression.  These observa- 
tions suggest that CD44 is participating in immunologic reac- 
tions, but the mechanisms are unclear.  CD44 may be pro- 
moting  cell  migration  into  the  site  of inflammation,  as 
suggested by Camp et al. (19), or enhancing cell-cell contact 
between effector and target cells, as suggested by Rodrigues 
Figure  5.  RT-PCR products 
from  sorted  HA-binding  and non- 
binding  spleen  cells.  RNA, cDNA 
and Southern blot were prepared 
as described  in Materials  and Me- 
thods. Cells  used for RNA were: 
HA-binding (lane A) and non- 
binding  (lane  B) spleen  cells  from 
7-d immune  mice, isolated  by cell 
sorting; and AKR1 cells trans- 
fected with CD44 isoforms  con- 
taining variant  exons v8-10 (lane 
C) and v9-10 (lane  D), described  in He et al. (10) as M2 and M1, respec- 
tively. The legend  indicates  bp, and the expected  size of standard CD44 
isoform is '-400 bp. 
386  Hyaluronan  Binding by CD44 during an In Vivo Immune Response et al. (20), as well as possibly contributing to cell activation 
signals. In any case, the natural ligand interacting with CD44 
in these systems  has  not been established. 
The studies described here demonstrate that the hyaluronan 
binding function of CD44 is activated during an in vivo ira- 
munologic response and that cells capable of CD44-mediated 
HA-binding are actively participating in the response. How- 
ever, the significance of HA binding by CD44 in an immune 
response, and, indeed, the function of CD44 itself, remains 
to be determined. 
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